A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Non-small Cell Lung Cancer|Gastric Carcinoma|Gastroesophageal Junction Carcinoma|Classical Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma|Peripheral T-cell Lymphoma|Cutaneous Melanoma|Head and Neck Squamous Cell Carcinoma|Bladder Cancer|Ovarian Cancer|Triple Negative Breast Cancer|Cervical Cancer
Interventions: DRUG: SEA-TGT|DRUG: sasanlimab|DRUG: brentuximab vedotin
Sponsor: Seagen Inc.